An EED inhibitor developed by Novartis is being evaluated in a phase 1 2 clinical trial for advanced malignancies including DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer, and sarcoma NCT02900651 <a href=https://nolvadex.one/>do tamoxifen side effects start immediately</a> 295, 7774 7788 2020
Comment Guidelines:
- Please keep comments and questions short and to the point.
- Try to keep things civil and overall try to keep the conversations respectful.
- No four letter words.
- No missionizing.
- Site moderators reserve the right to delete your comments if they do not follow the guidlines or are off-topic.
Comments:
There are no Comments to show. Comment and start the discussion.